Can you take SGLT2 and GLP-1 medicines together?

Yes. An SGLT2 inhibitor and a GLP-1 receptor agonist can be prescribed together, particularly for adults with type 2 diabetes. They work in different ways, so combining them can improve blood sugar control when one medicine is not enough. Heart disease, heart failure, kidney disease, and weight-management goals may also influence the decision.

The combination is not right for everyone. Your clinician needs to review the exact products, kidney function, other medications, and ability to eat and drink normally. Two important safety issues are dehydration and a rare SGLT2-related complication called ketoacidosis, which can occur even without very high blood sugar.

If different clinicians prescribe your medications, make sure each has your complete medication list before another treatment is added.

Why these two medication classes can be used together

Taking two medicines that affect blood sugar does not automatically mean they duplicate each other. The important questions are how they work, what each is intended to treat, and whether their combined benefits justify the added risks and treatment burden.

SGLT2 inhibitors work through the kidneys

SGLT2 stands for sodium-glucose cotransporter 2, a protein involved in moving filtered glucose back into the bloodstream. SGLT2 inhibitors block some of that glucose reabsorption, allowing more glucose to leave the body through urine.

Examples include empagliflozin, sold as Jardiance, and dapagliflozin, sold as Farxiga. These are oral medicines. The exact product matters because approved uses and kidney-function considerations differ.

Some SGLT2 products have uses involving heart failure or chronic kidney disease, including in certain people without diabetes. A prescription may therefore serve a purpose beyond lowering glucose. Understanding that purpose helps explain why a clinician might continue an SGLT2 medicine even when blood sugar readings improve.

GLP-1 receptor agonists affect glucose regulation and appetite

GLP-1 stands for glucagon-like peptide 1, a hormone involved in blood sugar regulation. GLP-1 receptor agonists activate its receptors. They help the pancreas release insulin in a glucose-dependent way, reduce inappropriate glucagon signaling, and can slow stomach emptying. They also affect appetite and fullness.

Examples include semaglutide, dulaglutide, and liraglutide. GLP-1 treatment includes injectable and oral products, so the class name alone does not tell you how to take a particular prescription.

These actions differ from glucose removal through the kidneys. That provides a practical reason to combine the classes: a clinician can address blood sugar through more than one pathway. A review of combination treatment in type 2 diabetes describes these complementary mechanisms and the clinical evidence supporting their use together.

Tirzepatide is related but distinct. It acts at both GIP and GLP-1 receptors, whereas semaglutide acts at GLP-1 receptors. Evidence for one specific drug combination should not be assumed to establish identical results for every related medicine.

What benefits can the combination offer?

The expected benefit should be specific enough to evaluate. “Better diabetes treatment” is less useful than knowing whether the goal is a lower A1C, treatment of a particular heart or kidney condition, weight management, or several of these together.

Better blood sugar control when one medicine is insufficient

Adding a medicine from the other class can lower blood sugar further in adults with type 2 diabetes. A1C, a blood test reflecting average glucose over roughly the previous three months, helps clinicians assess the longer-term response.

The amount of improvement depends on the starting A1C, the products used, kidney function, other treatment, and how consistently the medicines can be taken. You cannot reliably add together the advertised effects of two separate drugs to predict your result.

A higher starting A1C also changes how a study result should be interpreted. Someone beginning near their individualized goal may not experience the same reduction as someone whose glucose is substantially above target.

The decision is therefore not simply whether two drugs “work together.” It is whether the additional treatment is likely to address an unmet need without making daily care unnecessarily complicated.

Weight changes may be helpful, but are not guaranteed

Both classes can reduce body weight, although their effects differ by medication and population. For someone with type 2 diabetes who is also living with obesity, weight change may be a meaningful part of the treatment discussion.

However, SGLT2 inhibitors are not FDA-approved weight-loss medicines. Adding one solely to increase weight loss is a different decision from treating diabetes, heart failure, or kidney disease and should not be treated as a routine strategy.

Likewise, a diabetes combination study does not establish the expected weight loss for someone without diabetes who is using an obesity-treatment product. The formulation, indication, dose studied, and other medications all matter.

If weight management is your main goal, compare approved weight-management options on their own evidence and suitability rather than assuming that more glucose-lowering medicines will produce a better result.

Helimeds' Wegovy treatment information describes that branded option; prescribing still depends on clinical assessment.

Heart and kidney considerations can influence treatment

Selected medicines in these classes have demonstrated benefits for particular heart or kidney outcomes in defined populations. Those benefits are an important reason treatment decisions may extend beyond A1C.

Still, evidence that each medicine has benefits separately does not prove that combining them doubles protection. The answer depends on the specific drugs, condition, and outcome being considered.

A 2025 observational study of adults with both heart failure and type 2 diabetes compared people receiving an SGLT2 inhibitor plus a GLP-1 receptor agonist with people receiving an SGLT2 inhibitor alone. After matching the groups on recorded characteristics, combination treatment was associated with lower risks of death and hospitalization over one year.

That finding is encouraging, but it does not establish cause and effect. Treatment was not randomly assigned, and differences in health, access to care, or prescribing decisions could still affect the results. It also does not predict the benefit for a person without both conditions.

Which risks need attention when the medicines are combined?

The combination brings together the safety considerations of both prescriptions. Some effects are separate, while others can interact through reduced food intake, fluid loss, or changes in glucose.

Dehydration can become more likely if eating or drinking falls

An SGLT2 medicine can increase fluid loss through urination. A GLP-1 medicine can cause nausea, vomiting, diarrhea, or reduced appetite. If those effects occur together, maintaining adequate fluid intake can become harder.

Dizziness when standing, unusual weakness, reduced urination, or inability to keep fluids down deserves prompt attention. These symptoms can have several causes and should not be interpreted as evidence that treatment is working.

Hydration advice also needs to fit your health conditions. Someone with a prescribed fluid restriction for heart failure or kidney disease should not simply increase water intake without guidance. Ask your clinician what fluid intake and symptoms should guide your plan.

Ketoacidosis can occur without very high blood sugar

SGLT2 inhibitors can cause diabetic ketoacidosis, a dangerous buildup of acids called ketones. Unlike the pattern many people associate with diabetes emergencies, blood sugar may not be markedly elevated.

Risk can increase during acute illness, prolonged fasting, very low food intake, dehydration, heavy alcohol use, or an inappropriate reduction in insulin. A ketogenic diet is therefore important to discuss before taking an SGLT2 inhibitor.

The FDA warning about SGLT2 inhibitors and ketoacidosis identifies symptoms including nausea, vomiting, abdominal pain, unusual tiredness, and trouble breathing. Seek urgent medical evaluation for symptoms suggesting ketoacidosis rather than waiting for a very high glucose reading.

A normal-looking glucose reading does not rule out SGLT2-related ketoacidosis.

This distinction is especially important when a GLP-1 medicine is also being used, because nausea or abdominal discomfort could otherwise be mistaken for an expected digestive side effect. Severe symptoms, worsening illness, or inability to drink require assessment.

Low blood sugar risk depends on the rest of the regimen

Used without insulin or medicines that stimulate insulin release, these two classes generally have a lower risk of hypoglycemia, or low blood sugar, than some other diabetes treatments. That does not make the risk zero.

Insulin and sulfonylureas, such as glipizide or glimepiride, change the calculation. Your clinician may need to review those prescriptions when another glucose-lowering medicine is added. Do not reduce insulin on your own, because an inappropriate reduction can contribute to ketoacidosis.

Ask how often to check glucose and what to do if readings fall below your individualized target. Shaking, sweating, hunger, dizziness, or confusion may signal low blood sugar. Severe confusion, unconsciousness, or inability to swallow is an emergency requiring 911.

For a closer look at that part of the regimen, Helimeds' guide to taking a GLP-1 medicine with insulin discusses coordinated monitoring and clinician-directed adjustments.

Each medicine still has its own important warnings

GLP-1 safety information varies by product. For semaglutide products such as Wegovy, the boxed warning concerns thyroid C-cell tumors observed in rodents; whether this risk applies to humans is unknown. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, called MEN 2. This does not mean that every thyroid condition rules out treatment.

A suitability review should also address pancreatitis, gallbladder disease, severe digestive problems, dehydration-related kidney injury, serious allergic reactions, and relevant diabetes-related eye disease. The Wegovy prescribing information provides product-specific warnings, rather than a universal instruction sheet for every GLP-1 medicine.

Helimeds' safety-information resources provide additional label navigation, but do not replace the prescribing information for your exact product.

SGLT2 treatment adds infection considerations. Report genital itching or irritation, painful urination, or other infection symptoms. Fever with back or flank pain, or severe pain, swelling, or redness around the genitals or the area between the genitals and anus, warrants urgent assessment.

Severe persistent abdominal pain, especially with vomiting, also needs urgent evaluation. Trouble breathing, facial or throat swelling, collapse, or serious chest symptoms require emergency care.

Who needs a more individualized review?

Kidney function is central to this decision, but a single laboratory number does not answer every question. An SGLT2 medicine’s glucose-lowering effect and its suitability for a heart or kidney indication are separate considerations. The exact product and reason for treatment determine how kidney results are interpreted.

Your clinician may also review blood pressure, urine albumin, current fluid status, and other medications. Urine albumin is a marker of kidney damage; estimated glomerular filtration rate, or eGFR, estimates how well the kidneys filter blood.

Bring up any of the following before treatment is added:

• Previous ketoacidosis, type 1 diabetes, or uncertainty about your diabetes diagnosis.

• Frequent vomiting, severe constipation, gastroparesis, or difficulty maintaining food and fluid intake.

• Recurrent genital infections, serious urinary infections, or trouble emptying your bladder.

• Low blood pressure, fainting, dehydration, or use of diuretics, sometimes called water pills.

• Previous pancreatitis, gallbladder problems, diabetic eye disease, or relevant thyroid-cancer history.

• Pregnancy, pregnancy plans, breastfeeding, upcoming surgery, or a procedure involving fasting.

These details do not all mean the combination is prohibited. They identify questions that may change the product choice, monitoring plan, or whether adding treatment is appropriate.

Pregnancy and breastfeeding advice must come from the exact products’ information and your treating clinician. If pregnancy is possible or planned, arrange that conversation before starting or changing treatment rather than applying one drug’s instructions to the whole class.

Does the exact GLP-1 product or formulation change the answer?

Yes. “GLP-1” is a category, not a complete prescription identity. The active ingredient, brand, formulation, route, and approved use all affect how a combination should be assessed.

Ozempic and Wegovy both contain semaglutide, but they are different products with different indication lists and product instructions. Mounjaro and Zepbound contain tirzepatide, which acts at both GIP and GLP-1 receptors. Their names should not be used interchangeably.

A GLP-1 medicine prescribed for weight management does not automatically replace a diabetes treatment. Conversely, an SGLT2 prescription for heart failure does not establish that someone has diabetes. Understanding why each prescription exists prevents mistaken assumptions about what can be discontinued.

Oral and injectable formulations also have different administration requirements. Whether medicines can be part of the same treatment plan is separate from whether tablets can be swallowed at the same moment. Follow each prescription’s instructions, and ask the pharmacist to resolve timing questions without inventing a separation interval.

Compounded preparations require a separate discussion

Compounded semaglutide or compounded tirzepatide should not be treated as interchangeable with a branded FDA-approved product. Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness, and quality before marketing.

Helimeds also provides compounded GLP-1 treatment information, separate from its branded-product information.

Research involving branded GLP-1 products is not a trial of a particular pharmacy’s compounded preparation. The FDA’s information on unapproved GLP-1 products explains why product identity and dispensing information matter.

If a compounded preparation is being considered, provide your diabetes clinician with the exact ingredient, pharmacy label, prescribed amount, and concentration. Milligrams describe the amount of drug, milliliters describe liquid volume, and syringe units are device markings. Resolve unclear instructions with the prescriber or dispensing pharmacist before injecting.

How to prepare for a safe combination-treatment plan

A useful consultation should leave you knowing why each medicine is prescribed, what will be monitored, and whom to contact if problems arise. It should also account for affordability and practical use, because a plan that is difficult to maintain may not deliver its intended benefit.

Bring your medication bottles or clear label photographs, recent laboratory results, glucose records if available, and a description of any symptoms. Include nonprescription medicines, supplements, and recent changes in eating patterns.

Ask your clinician or pharmacist:

• What additional benefit are we trying to achieve by combining these medicines?

• Does my kidney function support this exact SGLT2 product for its intended use?

• Do insulin, a sulfonylurea, a diuretic, or another prescription need clinician-directed review?

• Which glucose readings, blood pressure changes, or symptoms should prompt contact?

• What should I do if I am vomiting, cannot eat, or cannot keep fluids down?

• When would ketone testing be appropriate, and what should I do with the result?

• What follow-up tests and appointments will assess benefit and tolerability?

• What is the plan if cost, coverage, side effects, or access interrupt treatment?

Obtain illness and procedure instructions in advance

Ask for a written sick-day plan before you become ill. It should explain which circumstances require contacting the care team, whether a medication should be temporarily withheld, and how restarting will be decided. Do not assume that every minor illness calls for the same response.

Surgery and procedures need a separate plan. Fasting and surgical stress matter for SGLT2-related ketoacidosis, while delayed stomach emptying with GLP-1 treatment matters for anesthesia and deep sedation. Tell the procedural and anesthesia teams about both medicines well in advance.

There is no single medication-withholding schedule appropriate for every product and procedure. Do not copy an online schedule or borrow instructions from someone taking a different medicine.

Keep prescribing decisions coordinated

If weight-management treatment is being considered through Helimeds, disclose your SGLT2 prescription and the clinician managing your diabetes, heart failure, or kidney disease. Starting a separate intake should not create a separate, incomplete medication record.

Helimeds’ pathway begins with a medical intake and consultation with a licensed provider. Treatment may be prescribed only if clinically appropriate and permitted in your state, with fulfillment handled through a licensed pharmacy partner. Further testing or in-person care may be needed.

The goal is one coordinated medication plan, even when more than one clinician is involved.

Medication changes belong with the treating clinician. A pharmacist can help clarify dispensing instructions and administration, while customer support handles service or order questions rather than assessing concerning symptoms.

Conclusion

An SGLT2 inhibitor and a GLP-1 medicine can be used together, especially in type 2 diabetes when their different actions address a clear treatment need. The combination may improve glucose control and can fit a broader plan involving weight, heart health, or kidney health.

The next step is a complete medication review, not adding either drug independently. Bring the exact product names, kidney results, glucose records, and any digestive or hydration problems. Before treatment begins, obtain clear monitoring, sick-day, and procedure instructions, with particular attention to ketoacidosis and other medicines that can cause low blood sugar.

If Zepbound is being considered for weight management, review Helimeds' Zepbound treatment information; any prescription requires clinical assessment and coordination with your existing care.

This article provides general health information and does not replace advice from your licensed healthcare professional.

Frequently asked questions

Can I take Jardiance and Ozempic together?

Jardiance contains empagliflozin, an SGLT2 inhibitor, and Ozempic contains semaglutide, a GLP-1 receptor agonist. They can be prescribed together for some adults with type 2 diabetes, but suitability depends on kidney function, other medicines, treatment goals, and individual risks. Make sure both prescribers know your complete medication list.

Do an SGLT2 inhibitor and a GLP-1 medicine need to be taken hours apart?

There is no universal spacing rule for these two medication classes. Administration requirements depend on the exact products, particularly whether the GLP-1 medicine is oral or injectable. Follow each label and ask your pharmacist to check the timing of your full regimen.

Can someone without diabetes take both medicines?

Some SGLT2 products have heart failure or kidney disease uses in defined populations without diabetes, and certain GLP-1 products have weight-management uses. Having a potential indication for each does not automatically make the combination appropriate. A clinician needs to assess the reason for each prescription and the combined safety considerations.

Is nausea always an expected GLP-1 side effect when taking both?

No. Although GLP-1 medicines can cause nausea, an SGLT2 inhibitor adds the possibility of ketoacidosis, which may also cause vomiting, abdominal pain, unusual tiredness, or trouble breathing. Seek urgent assessment for concerning symptoms even if your glucose is not very high, especially when you cannot eat or drink normally.